# Stage III NSCLC RWE in Chinese Patients

> **NCT04023812** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 500 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04023812
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-16
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023812, "Stage III NSCLC RWE in Chinese Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04023812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*